arrow
S

Shinji Nakamichi

national institutes of health (nih) - usa
H指数:15
被引数:842

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
2024-04-133
OAAI
Phosphoproteomic Analysis Identi fied Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

磷酸化蛋白质组学分析证实FAK和Src的相互磷酸化是EGFR突变肺癌中奥希替尼耐药的机制

2024-04-012
OA
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study)
2024-01-021
OAAI
A Phase Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q)
2024-01-011
OAAI
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors

日本晚期实体瘤患者中MEK抑制剂RO4987655的I期和药代动力学/药效学研究

2015-03-278
PREAI
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer

抗MET抗体onartuzumab在实体瘤和MET阳性肺癌患者中的I期研究

2015-03-1812
PREAI
Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non-Small-Cell Lung Cancer
2015-01-0150
PREAI